🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
ANT
$ANTX
🔒 US EquitiesAN2 Therapeutics, Inc.
AVG HISTORICAL GAP
-0.15%
MAX GAP RECORD
-5.93%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $ANTX
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$ANTX
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Aug 11, 2026 Earnings Release 2026-08-11 (AFTER CLOSE) |
+3.75%
|
| May 11, 2026 Earnings Release 2026-05-11 (AFTER CLOSE) |
-2.97%
|
| Mar 17, 2026 Earnings Release 2026-03-17 (AFTER CLOSE) |
-3.00%
|
| Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE) |
-5.93%
|
| Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE) |
+0.95%
|
| May 13, 2025 Earnings Release 2025-05-13 (AFTER CLOSE) |
-1.69%
|
| Mar 25, 2025 Earnings Release 2025-03-25 (AFTER CLOSE) |
-0.67%
|
| Nov 13, 2024 Earnings Release 2024-11-13 (AFTER CLOSE) |
+1.98%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
2.5%
Bullish Gaps (5)
Bearish Gaps (6)
Neutral / Flat (3)
📖 Intelligence Summary
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗